Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 76 entries
Sorted by: Best Match Show Resources per page
Temporal trends of nonalcoholic fatty liver disease–related hepatocellular carcinoma in the veteran affairs population

veteran

Mittal S, El-Serag HB.
GSID: FO2K9iTrlHgJ
S Mittal, YH Sada, HB El-Serag, F Kanwal… - Clinical …, 2015 - Elsevier

Background & Aims Nonalcoholic fatty liver disease (NAFLD) is a risk factor for hepatocellular carcinoma (HCC). However, no systemic studies from the United States have examined …

Cite
Mittal, S., Sada, Y. H., El-Serag, H. B., Kanwal, F., Duan, Z., Temple, S., ... & Davila, J. A. (2015). Temporal trends of nonalcoholic fatty liver disease–related hepatocellular carcinoma in the veteran affairs population. Clinical Gastroenterology and Hepatology, 13(3), 594-601.
Mittal, Sahil, et al. "Temporal trends of nonalcoholic fatty liver disease–related hepatocellular carcinoma in the veteran affairs population." Clinical Gastroenterology and Hepatology 13.3 (2015): 594-601.
Copy Download .nbib Format: MLA
A Farewell From the Board of Editors of the Blue Journal.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

El-Serag HB.
PMID: 28528938
Clin Gastroenterol Hepatol. 2017 Jun;15(6):797-798. doi: 10.1016/j.cgh.2017.03.008.

No abstract available.

Cite
El-Serag HB. A Farewell From the Board of Editors of the Blue Journal. Clin Gastroenterol Hepatol. 2017;15(6):797-798doi: 10.1016/j.cgh.2017.03.008.
El-Serag, H. B. (2017). A Farewell From the Board of Editors of the Blue Journal. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 15(6), 797-798. https://doi.org/10.1016/j.cgh.2017.03.008
El-Serag, Hashem B. "A Farewell From the Board of Editors of the Blue Journal." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 15,6 (2017): 797-798. doi: https://doi.org/10.1016/j.cgh.2017.03.008
El-Serag HB. A Farewell From the Board of Editors of the Blue Journal. Clin Gastroenterol Hepatol. 2017 Jun;15(6):797-798. doi: 10.1016/j.cgh.2017.03.008. PMID: 28528938.
Copy Download .nbib Format: NLM
Uscharin, the most potent molluscicidal compound tested against land snails.

Journal of chemical ecology

Hussein HI, Kamel A, Abou-Zeid M, Abdel-Khalek, El-Sebae H, Saleh MA.
PMID: 24241704
J Chem Ecol. 1994 Jan;20(1):135-40. doi: 10.1007/BF02065996.

Calotropis procera, is a shrub with broad ovate fleshy leaves that grows wild in the Egyptian deserts. The plant was discovered to be highly toxic to the land snailsThepa pisana. The active ingredient responsible for the molluscicidal activity was...

Cite
Hussein HI, Kamel A, Abou-Zeid M, et al. Uscharin, the most potent molluscicidal compound tested against land snails. J Chem Ecol. 1994;20(1):135-40doi: 10.1007/BF02065996.
Hussein, H. I., Kamel, A., Abou-Zeid, M., Abdel-Khalek, El-Sebae, H., & Saleh, M. A. (1994). Uscharin, the most potent molluscicidal compound tested against land snails. Journal of chemical ecology, 20(1), 135-40. https://doi.org/10.1007/BF02065996
Hussein, H I, et al. "Uscharin, the most potent molluscicidal compound tested against land snails." Journal of chemical ecology vol. 20,1 (1994): 135-40. doi: https://doi.org/10.1007/BF02065996
Hussein HI, Kamel A, Abou-Zeid M, Abdel-Khalek, El-Sebae H, Saleh MA. Uscharin, the most potent molluscicidal compound tested against land snails. J Chem Ecol. 1994 Jan;20(1):135-40. doi: 10.1007/BF02065996. PMID: 24241704.
Copy Download .nbib Format: NLM
Manuscript writing.

Gastrointestinal endoscopy

El-Serag HB.
PMID: 18226694
Gastrointest Endosc. 2008 Feb;67(2):311-2. doi: 10.1016/j.gie.2007.07.023.

No abstract available.

Cite
El-Serag HB. Manuscript writing. Gastrointest Endosc. 2008;67(2):311-2doi: 10.1016/j.gie.2007.07.023.
El-Serag, H. B. (2008). Manuscript writing. Gastrointestinal endoscopy, 67(2), 311-2. https://doi.org/10.1016/j.gie.2007.07.023
El-Serag, Hashem B. "Manuscript writing." Gastrointestinal endoscopy vol. 67,2 (2008): 311-2. doi: https://doi.org/10.1016/j.gie.2007.07.023
El-Serag HB. Manuscript writing. Gastrointest Endosc. 2008 Feb;67(2):311-2. doi: 10.1016/j.gie.2007.07.023. PMID: 18226694.
Copy Download .nbib Format: NLM
Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma.

International journal of molecular epidemiology and genetics

Jiao L, Chen L, Alsarraj A, Ramsey D, Duan Z, El-Serag HB.
PMID: 23205181
Int J Mol Epidemiol Genet. 2012;3(4):294-304. Epub 2012 Nov 15.

Receptor for advanced glycation end products (RAGE) plays an important role in promoting chronic inflammation with activation of NF-κB. Soluble form of RAGE (sRAGE) represents a naturally occurring competitive inhibitor of RAGE-mediated events. In a colonoscopy-based case-control study, we...

Cite
Jiao L, Chen L, Alsarraj A, et al. Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. Int J Mol Epidemiol Genet. 2012;3(4):294-304
Jiao, L., Chen, L., Alsarraj, A., Ramsey, D., Duan, Z., & El-Serag, H. B. (2012). Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. International journal of molecular epidemiology and genetics, 3(4), 294-304.
Jiao, Li, et al. "Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma." International journal of molecular epidemiology and genetics vol. 3,4 (2012): 294-304.
Jiao L, Chen L, Alsarraj A, Ramsey D, Duan Z, El-Serag HB. Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma. Int J Mol Epidemiol Genet. 2012;3(4):294-304. Epub 2012 Nov 15. PMID: 23205181; PMCID: PMC3508542.
Copy Download .nbib Format: NLM
The renal and urologic complications of inflammatory bowel disease.

Inflammatory bowel diseases

El-Serag HB, Zwas F, Bonheim NA, Cirillo NW, Appel G.
PMID: 23282807
Inflamm Bowel Dis. 1997;3(3):217-24.

SUMMARY: : Extraintestinal manifestations of inflammatory bowel disease (IBD) are common. Clinically significant renal/urologic complications occur in 10-15% of patients with IBD. In this article, we review the incidence, pathogenesis, diagnosis, and management of the various renal/urologic complications. In...

Cite
El-Serag HB, Zwas F, Bonheim NA, et al. The renal and urologic complications of inflammatory bowel disease. Inflamm Bowel Dis. 1997;3(3):217-24
El-Serag, H. B., Zwas, F., Bonheim, N. A., Cirillo, N. W., & Appel, G. (1997). The renal and urologic complications of inflammatory bowel disease. Inflammatory bowel diseases, 3(3), 217-24.
El-Serag, H B, et al. "The renal and urologic complications of inflammatory bowel disease." Inflammatory bowel diseases vol. 3,3 (1997): 217-24.
El-Serag HB, Zwas F, Bonheim NA, Cirillo NW, Appel G. The renal and urologic complications of inflammatory bowel disease. Inflamm Bowel Dis. 1997;3(3):217-24. PMID: 23282807.
Copy Download .nbib Format: NLM
Surveillance for hepatocellular carcinoma: in whom and how?.

Therapeutic advances in gastroenterology

El-Serag HB, Davila JA.
PMID: 21317990
Therap Adv Gastroenterol. 2011 Jan;4(1):5-10. doi: 10.1177/1756283X10385964.

No abstract available.

Cite
El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how?. Therap Adv Gastroenterol. 2011;4(1):5-10doi: 10.1177/1756283X10385964.
El-Serag, H. B., & Davila, J. A. (2011). Surveillance for hepatocellular carcinoma: in whom and how?. Therapeutic advances in gastroenterology, 4(1), 5-10. https://doi.org/10.1177/1756283X10385964
El-Serag, Hashem B, and Davila, Jessica A. "Surveillance for hepatocellular carcinoma: in whom and how?." Therapeutic advances in gastroenterology vol. 4,1 (2011): 5-10. doi: https://doi.org/10.1177/1756283X10385964
El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how?. Therap Adv Gastroenterol. 2011 Jan;4(1):5-10. doi: 10.1177/1756283X10385964. PMID: 21317990; PMCID: PMC3036965.
Copy Download .nbib Format: NLM
Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1.

Gastroenterology research and practice

Shobassy M, Husainat N, Tabash A, Patel K, El-Serag HB, Othman MO.
PMID: 31485218
Gastroenterol Res Pract. 2019 Aug 14;2019:5290642. doi: 10.1155/2019/5290642. eCollection 2019.

BACKGROUND AND AIMS: Fecal elastase-1 (FE-1) as a screening test for exocrine pancreatic insufficiency (EPI) is gaining popularity in clinical practice. The role of imaging in patients with FE-1-related suspicion of EPI remains unclear. The aim of this study...

Cite
Shobassy M, Husainat N, Tabash A, et al. Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterol Res Pract. 2019;2019:5290642doi: 10.1155/2019/5290642.
Shobassy, M., Husainat, N., Tabash, A., Patel, K., El-Serag, H. B., & Othman, M. O. (2019). Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterology research and practice, 20195290642. https://doi.org/10.1155/2019/5290642
Shobassy, Mazen, et al. "Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1." Gastroenterology research and practice vol. 2019 (2019): 5290642. doi: https://doi.org/10.1155/2019/5290642
Shobassy M, Husainat N, Tabash A, Patel K, El-Serag HB, Othman MO. Endoscopic Ultrasound Findings in Patients Diagnosed with Exocrine Pancreatic Insufficiency by Low Fecal Elastase-1. Gastroenterol Res Pract. 2019 Aug 14;2019:5290642. doi: 10.1155/2019/5290642. eCollection 2019. PMID: 31485218; PMCID: PMC6710758.
Copy Download .nbib Format: NLM
Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels.

Gastroenterology

El-Serag HB.
PMID: 30076836
Gastroenterology. 2018 Sep;155(3):607-609. doi: 10.1053/j.gastro.2018.07.036. Epub 2018 Aug 01.

No abstract available.

Cite
El-Serag HB. Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels. Gastroenterology. 2018;155(3):607-609doi: 10.1053/j.gastro.2018.07.036.
El-Serag, H. B. (2018). Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels. Gastroenterology, 155(3), 607-609. https://doi.org/10.1053/j.gastro.2018.07.036
El-Serag, Hashem B. "Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels." Gastroenterology vol. 155,3 (2018): 607-609. doi: https://doi.org/10.1053/j.gastro.2018.07.036
El-Serag HB. Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels. Gastroenterology. 2018 Sep;155(3):607-609. doi: 10.1053/j.gastro.2018.07.036. Epub 2018 Aug 01. PMID: 30076836; PMCID: PMC6366444.
Copy Download .nbib Format: NLM
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.

Hepatology (Baltimore, Md.)

Kramer JR, Natarajan Y, Dai J, Yu X, Li L, El-Serag HB, Kanwal F.
PMID: 34779535
Hepatology. 2021 Nov 15; doi: 10.1002/hep.32244. Epub 2021 Nov 15.

BACKGROUND AND AIMS: In patients with NAFLD, those with type 2 diabetes mellitus (DM) have a high risk of progression to HCC. However, the determinants of HCC risk in these patients remain unclear.APPROACH AND RESULTS: We assembled a retrospective...

Cite
Kramer JR, Natarajan Y, Dai J, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2021;doi: 10.1002/hep.32244.
Kramer, J. R., Natarajan, Y., Dai, J., Yu, X., Li, L., El-Serag, H. B., & Kanwal, F. (2021). Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32244
Kramer, Jennifer R, et al. "Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32244
Kramer JR, Natarajan Y, Dai J, Yu X, Li L, El-Serag HB, Kanwal F. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2021 Nov 15; doi: 10.1002/hep.32244. Epub 2021 Nov 15. PMID: 34779535.
Copy Download .nbib Format: NLM
A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Montealegre JR, Singal AG, Asrani SK, El-Serag H.
PMID: 34274512
Clin Gastroenterol Hepatol. 2021 Jul 16; doi: 10.1016/j.cgh.2021.07.024. Epub 2021 Jul 16.

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide and one of the few cancers with a rising mortality in the United States. There are opportunities for intervention along the cancer care continuum (CCC), which includes...

Cite
Montealegre JR, Singal AG, Asrani SK, et al. A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.07.024.
Montealegre, J. R., Singal, A. G., Asrani, S. K., El-Serag, H. (2021). A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.07.024
Montealegre, J R, et al. "A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.07.024
Montealegre JR, Singal AG, Asrani SK, El-Serag H. A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clin Gastroenterol Hepatol. 2021 Jul 16; doi: 10.1016/j.cgh.2021.07.024. Epub 2021 Jul 16. PMID: 34274512.
Copy Download .nbib Format: NLM
Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas.

Open forum infectious diseases

Kim HS, Guerrero R, Reader SW, Daheri M, Balakrishnan M, Troisi CL, El-Serag HB, Thrift AP.
PMID: 32665957
Open Forum Infect Dis. 2020 Jun 02;7(7):ofaa191. doi: 10.1093/ofid/ofaa191. eCollection 2020 Jul.

A community outreach hepatitis C virus (HCV) infection screening program provided low yield of detecting HCV-infected patients, linking them to our hepatology clinic for treatment. Our data underscore that most of the yield was related to addiction centers and...

Cite
Kim HS, Guerrero R, Reader SW, et al. Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open Forum Infect Dis. 2020;7(7):ofaa191doi: 10.1093/ofid/ofaa191.
Kim, H. S., Guerrero, R., Reader, S. W., Daheri, M., Balakrishnan, M., Troisi, C. L., El-Serag, H. B., & Thrift, A. P. (2020). Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open forum infectious diseases, 7(7), ofaa191. https://doi.org/10.1093/ofid/ofaa191
Kim, Hyun-Seok, et al. "Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas." Open forum infectious diseases vol. 7,7 (2020): ofaa191. doi: https://doi.org/10.1093/ofid/ofaa191
Kim HS, Guerrero R, Reader SW, Daheri M, Balakrishnan M, Troisi CL, El-Serag HB, Thrift AP. Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open Forum Infect Dis. 2020 Jun 02;7(7):ofaa191. doi: 10.1093/ofid/ofaa191. eCollection 2020 Jul. PMID: 32665957; PMCID: PMC7336547.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 76 entries